58 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
establishment located in a Listed Jurisdiction to which the ordinary shares are attributable; or
(iii)
holds our ordinary shares with the main purpose or one … to bank savings, other investments and liabilities will for this purpose be ignored if the holder of our ordinary shares cannot sufficiently
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
Supplement or the Prospectus, or the effectiveness of the Registration Statement, has been issued by the Commission, and no proceedings for such purpose … of the Placement Shares for offering or sale in any jurisdiction or of the initiation or threatening of any proceeding for any such purpose
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
but have compared the published data for Avacopan to data from our Phase 1 clinical trial of INF904. For the purpose of conducting pre-clinical studies
6-K
EX-99.2
f9mc3hd
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
424B5
kus4dw4nb
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
EX-4.3
ortsx1b22ne5qe uqns5
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.2
bo7kr2 pbp97r
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.2
easu85x8 z9
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
85isxd
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
wqokd
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-1.1
xtfgcn5 k9q
13 Apr 23
Current report (foreign)
4:01pm
424B5
7theuc txdh
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
jrxywo wjz
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-10.1
ism0l itrgn1
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.1
s01miltnvabdcd
6 Jul 22
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
8:30am